U.S. market Closed. Opens in 9 hours 55 minutes

IKNA | Ikena Oncology, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 1.6900 - 1.7250
52 Week Range 1.2200 - 2.3200
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 63,756
Average Volume 53,339
Shares Outstanding 48,258,100
Market Cap 82,521,351
Sector Healthcare
Industry Biotechnology
IPO Date 2021-03-26
Valuation
Profitability
Growth
Health
P/E Ratio -1.39
Forward P/E Ratio N/A
EPS -1.23
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 18
Country USA
Website IKNA
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
*Chart delayed
Analyzing fundamentals for IKNA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see IKNA Fundamentals page.

Watching at IKNA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on IKNA Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙